Delaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures by Wirth, Manfred
Eur Urol 2001;40(suppl 2):17–23
Delaying/Reducing the Risk of
Clinical Tumour Progression after
Primary Curative Procedures
M. Wirth
Department of Urology, Technical University of Dresden, Germany
Prof. M. Wirth
Universitätsklinikum Carl Gustav Carus
Klinik und Poliklinik für Urologie, Technische Universität Dresden
Fetscher Strasse 74, D–01307 Dresden (Germany)
Tel. +49 351 458 4447, Fax +49 351 458 4333, E-Mail wirth-m@rcs1.urz.tu-dresden.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2001 S. Karger AG, Basel
0302–2838/01/0408–0017$17.50/0
Accessible online at:
www.karger.com/journals/eur
Key Words
Prostate cancer W Antiandrogen W Bicalutamide W
Immediate therapy W Adjuvant therapy
Abstract
The advent of prostate-specific antigen (PSA) testing and
increased patient awareness has led to patients being
diagnosed with prostate cancer at an earlier stage and a
younger age than previously. Adjuvant hormonal therapy
to radiotherapy or prostatectomy has been shown to
reduce the risk of tumour progression, and in some stud-
ies survival benefits have been demonstrated. The non-
steroidal antiandrogen bicalutamide (‘Casodex’) has un-
dergone extensive evaluation and is currently undergoing
clinical trials as immediate therapy, either alone or as
adjuvant to treatment of curative intent in patients with
localized or locally advanced disease. Data from the first
analysis of one of the studies in the Early Prostate Cancer
(EPC) programme involving 3,603 patients have shown
that, after a median follow-up of 2.6 years, the risk of pros-
tate cancer progression was significantly reduced (by
43%) in patients receiving bicalutamide 150 mg compared
with those receiving standard care alone (HR 0.57; 95%
CI 0.48, 0.69; p N 0.0001). The risk of PSA progression was
also significantly reduced (by 63%). At this stage the sur-
vival data are still immature. Side effects of bicalutamide
were mostly gynaecomastia and breast pain, which is con-
sistent with its pharmacology. Overall withdrawal rates
were similar in the bicalutamide 150 mg and standard care
alone groups. In the bicalutamide 150 mg group, with-
drawals were mainly due to side effects, whereas in the
group receiving standard care alone, withdrawals were
mainly due to disease progression. The programme is
ongoing, and survival data are awaited.
Copyright © 2001 S. Karger AG, Basel
Introduction
Prostate cancer is one of the leading causes of mortality
in men, with the highest incidence of new cancer diagno-
sis [1]. The incidence of prostate cancer has increased due
to improved awareness and diagnosis, with improved
testing for prostate-specific antigen (PSA) levels enabling
the disease to be detected at an earlier stage (clinically
localized and locally advanced disease). Prostate cancer
patients have increased longevity compared with patients
with other types of cancer, such as breast or lung, and life
expectancy can be more than 15 years [2]. Therefore,
tolerability of long-term therapy must be considered.
Many patients are sexually active, and so current thera-
pies, which often inhibit sexual function, are not always
desirable. In finding new treatment options, therapy must
not only delay disease progression and prolong survival
but must also provide a good quality of life [3].
‘Casodex’ and ‘Zoladex’ are trade marks of the AstraZeneca group of
companies
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Fig. 1. Probability of overall survival over a
10-year period following treatment with ra-
diotherapy plus goserelin compared with ra-
diotherapy alone [11] (reproduced with kind
permission from the Massachusetts Medical
Society).
Treatment Options for Prostate Cancer
One treatment for locally confined prostate cancer is
radical prostatectomy. Although 84.7% of men with pT1–
T2 disease remain progression free 10 years after surgery,
risk of disease progression is increased in patients with
focal capsular penetration or established capsular pene-
tration (67.7 vs. 58.4% remain progression-free 10 years
after surgery, respectively) [4]. Radiotherapy is an alter-
native option for patients who are not able, or do not
wish, to undergo surgery and for those patients with local-
ly advanced disease. Clinical trials have shown that a
patient with T1–T2, Nx disease (Gleason score 2–6) has a
28% risk of dying from prostate cancer 15 years after
radiotherapy, but a patient with T3, Nx or N+ disease
(Gleason score 8–10) has a 73% risk of dying from pros-
tate cancer 15 years after therapy [5].
In order to minimize the risk of disease progression,
and to minimize symptoms of prostate cancer for patients
who have undergone primary therapy, adjuvant hormon-
al therapy can be administered. Luteinizing hormone-
releasing hormone (LHRH) (agonists or antagonists) re-
duces androgen stimulation of tumour growth, as does
orchiectomy. However, withdrawal of androgens leads to
different side effects, such as impotence, osteoporotic
fractures [6] and lowered haemoglobin levels [7], and also
has negative psychological implications [8]. Therefore,
there is interest in using non-steroidal antiandrogens,
which do not have these side effects, in this setting.
Hormonal therapy can be initiated either immediately
after primary treatment or at a later date, once PSA levels
begin to rise or the patient begins to suffer from increased
symptoms. The timing of hormonal therapy may depend
upon the age of the patient, stage of disease and individual
preference. Currently, the most appropriate timing of hor-
monal therapy is still a subject of much debate.
Adjuvant Hormonal Therapy in the
Radiotherapy Setting
Administration of adjuvant therapy has the potential
to improve survival. Isaacs [9, 10] demonstrated that a
combination of chemotherapy and androgen ablation in-
creased survival of rats when compared with the therapies
given alone.
Clinical trials have since shown the beneficial effects of
adjuvant hormonal therapy. Radiotherapy plus adjuvant
hormonal therapy (goserelin [‘Zoladex’] 3.6 mg every 4
weeks for 3 years) administered to patients with locally
advanced prostate cancer (stage T3–4, N0–2, M0) re-
sulted in a significantly higher proportion of patients
remaining disease free after 5 years compared with radio-
therapy alone (85 vs. 48%, respectively; p ! 0.001) [11].
Overall survival after 5 years was 79% in the adjuvant
group compared with 62% in the group receiving radio-
therapy alone (p = 0.001; fig. 1) [11].
The Radiation Therapy Oncology Group (RTOG) con-
ducted a randomized Phase III trial of adjuvant goserelin
(3.6 mg indefinitely or until disease progression) in pa-
tients receiving radiotherapy for stage T1–T3 prostate
cancer [12]. After a median follow-up of 4.5 years there
was a statistically significant improvement in progres-
sion-free survival in patients receiving adjuvant therapy
compared with those receiving radiotherapy alone (84 vs.
71%; p ! 0.0001). The difference in 5-year overall surviv-
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al was not statistically significant between the two groups,
which may be due to all patients having early prostate
cancer with an overall low risk of disease progression.
However, in a planned subgroup analysis of patients with
a poor prognosis with a Gleason score of 8–10, the differ-
ence in 5-year overall survival rate was statistically signifi-
cant (66% in the group receiving adjuvant therapy and
55% in the radiotherapy group; p = 0.03) [12]. These data
demonstrate that hormonal treatment in addition to pri-
mary therapy, in patients with localized or locally ad-
vanced disease, delays the rate of disease progression and
can improve overall survival in some patients.
The benefits of adjuvant hormonal therapy in terms of
time to disease progression and overall survival were also
demonstrated by Granfors et al. [13]. Of 91 patients with
T1–4, N0–3, M0 prostate cancer at a median follow-up of
9.3 years, clinical progression was seen in 31% of patients
receiving adjuvant therapy (radiotherapy plus orchiecto-
my) and 61% of patients receiving radiotherapy alone (p =
0.005). Mortality from prostate cancer was 38% in the
adjuvant treatment group, and 61% in patients receiving
radiotherapy alone (p = 0.02). Only patients with lymph
node involvement receiving adjuvant therapy had a sig-
nificant difference in overall survival in comparison with
patients receiving radiotherapy alone (p ! 0.001). No sta-
tistically significant survival benefit was identified for
patients without lymph node involvement. However, 3
patients receiving adjuvant therapy refused an orchiecto-
my, although 2 eventually received treatment upon dis-
ease progression. Including these 3 patients with those
receiving radiotherapy alone, a significant difference for
disease-specific survival was seen between the two groups
(p = 0.02). The high incidence of progression in patients
receiving radiotherapy alone resulted in the trial being
stopped for ethical reasons before sufficient numbers of
patients were recruited for overall analysis. These find-
ings indicate that hormonal therapy adjuvant to radio-
therapy may delay disease progression, especially when
lymph nodes are involved.
Hanks et al. [14] studied the effects of adjuvant hor-
monal therapy for 24 months following primary therapy.
Patients (n = 1,554) with locally advanced disease (T2c–
T4) received goserelin plus flutamide for 2 months prior
to radiotherapy, and were then randomized to no further
therapy or to 24 months of additional goserelin alone.
After a follow-up of 4.8 years, disease-free survival had
increased in the group receiving goserelin therapy com-
pared with those who received no further therapy after
radiotherapy (54% vs. 34%; p = 0.0001) [14].
Adjuvant Hormonal Therapy in the Surgical
Setting
Adjuvant hormonal therapy has also proven to be ben-
eficial in delaying disease progression when used in con-
junction with radical prostatectomy. The potential bene-
fit of immediate adjuvant hormonal therapy in a surgical
setting was confirmed in a retrospective, non-randomized
study by Zincke et al. [15] who examined records for 370
patients with stage D1 (N+) disease who had undergone
radical prostatectomy with immediate or delayed adju-
vant hormonal therapy. After a median follow-up of 4.1
years, 10-year progression-free survival was significantly
higher for those receiving immediate adjuvant therapy
compared with those receiving delayed therapy (76% vs.
24%, respectively; p ! 0.0001).
In a randomized clinical trial, Messing et al. [16] dem-
onstrated the effects of adjuvant hormonal therapy (goser-
elin, 3.6 mg subcutaneously every 28 days or orchiecto-
my) after radical prostatectomy and pelvic lymphadenec-
tomy in patients with node-positive prostate cancer (n =
98). After a median follow-up of 7.1 years (range 3–10
years), only 6.4% of patients in the group receiving adju-
vant hormonal therapy died from prostate cancer, com-
pared with 31.4% of patients receiving deferred hormonal
therapy (HR 6.2; 95% CI 1.8, 21.5; p ! 0.01). Overall sur-
vival was also higher in those receiving immediate ther-
apy compared with those receiving deferred therapy
(85.2 vs. 64.7%, respectively; HR 3.0; 95% CI 1.2, 7.3;
p = 0.02; fig. 2) [16]. However, the results from this trial
need to be interpreted with caution because of the small
number of patients involved.
In a larger randomized study involving 201 patients
with early (T3) prostate cancer who had undergone radi-
cal prostatectomy, a 25.2% benefit in disease-free survival
was seen in patients receiving goserelin (3.6 mg every 28
days) compared with patients who received no treatment
after radical prostatectomy [17].
Interim analysis of a further study involving 283
patients with T3, pN0 disease has demonstrated that
patients receiving flutamide 250 mg adjuvant to prosta-
tectomy have significantly higher progression-free surviv-
al at 4 years compared with those undergoing radical pros-
tatectomy alone (90 vs. 69%, respectively; p = 0.0029)
[18]. Further follow-up is required in this study to estab-
lish whether overall survival is significantly improved by
adjuvant therapy.
Although hormonal therapy adjuvant to radiotherapy
or surgery appears to offer significant increases in time to
disease-progression and, in some patients, improved
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Fig. 2. Overall survival in patients receiving
prostatectomy plus adjuvant hormonal ther-
apy (orchiectomy or goserelin) compared
with prostatectomy and deferred hormonal
treatment [16] (reproduced with kind per-
mission from the Massachusetts Medical So-
ciety).
Fig. 3. Progression-free survival after treat-
ment with bicalutamide 150 mg in addition
to standard care or standard care alone [22]
(reproduced with kind permission from Else-
vier Science).
overall survival, there is a need for additional treatments
that are effective and well tolerated. The non-steroidal
antiandrogen bicalutamide (‘Casodex’) 150 mg seems to
fulfil these requirements and is currently undergoing
investigation as immediate therapy, either alone or as
adjuvant to standard therapy, in early prostate cancer.
Bicalutamide Therapy in Prostate Cancer
Bicalutamide 150 mg monotherapy has been shown to
provide a survival outcome that is not statistically differ-
ent to castration in locally advanced, non-metastatic pros-
tate cancer (T3–T4, M0–M1), while offering additional
quality of life and tolerability benefits [19]. Bicalutamide
does not decrease testosterone concentrations [20], unlike
medical or surgical castration, and this may be of particu-
lar relevance to patients as sexual potency is less likely to
be reduced. Of 480 patients with T3–T4, M0–M1 disease,
sexual interest was significantly higher in patients receiv-
ing bicalutamide 150 mg than castration (p = 0.029) [19].
The efficacy and tolerability of bicalutamide 150 mg in
early prostate cancer as immediate therapy, either alone
or as adjuvant therapy, in patients with localized or local-
ly advanced prostate cancer is currently being investi-
gated in the largest (n = 8,113) international prostate can-
cer programme to date [21]. The Early Prostate Cancer
(EPC) programme consists of three randomized, double-
blind, placebo-controlled, parallel-group trials. The trials
were designed and powered at the outset to support a
combined, per protocol analysis. Trial 23 is being carried
out in the USA and Canada and has enrolled 3,292
Mean age (range), years
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Table 1. Demography in Trial 24 in the EPC
programme [22] (adapted with kind
permission from Elsevier Science)
Bicalutamide 150 mg
(n = 1,798)
Standard care alone
(n = 1,805)
68.6 (42–93) 68.7 (46–93)
Preprocedure PSA geometric mean, Ìg/l 12.5 11.9
Stage of disease, %
T1/T2 64.3 66.3
T3 33.2 31.2
T4 2.6 2.5
Nodal status, %
N0 61.3 60.4
Nx 36.0 36.9
N+ 2.6 2.7
Prior therapy, %
Radical prostatectomy 44.9 43.4
Radiotherapy 18.6 18.0
Watchful waiting 34.9 36.9
Radical prostatectomy plus radiotherapy 1.6 1.6
Fig. 4. Incidence of bone scan confirmed progression after treatment
with bicalutamide 150 mg in addition to standard care or standard
care alone.
patients, Trial 24 has 3,603 patients recruited from Eu-
rope, Australia, South Africa, Israel and Mexico, and
Trial 25 has 1,218 patients in Denmark, Norway, Finland
and Sweden.
Primary endpoint data for time to progression are now
available for Trial 24 [22]. Patients with stage T1b–T4,
any nodal status, M0 prostate cancer were randomised to
receive bicalutamide 150 mg or placebo once daily (oral
dose). Patients had received no previous therapy (35.9%),
radical prostatectomy (44.2%), radiotherapy (18.3%) or
radical prostatectomy plus radiotherapy (1.6%). The
treatment groups were well matched for demography,
tumour stage and grade, nodal status and prior therapy
(table 1) [22].
Bicalutamide 150 mg or placebo was administered
once daily, and the recommended duration of treatment
was 5 years when given as adjuvant therapy or until dis-
ease progression in patients undergoing watchful waiting.
Of the 3,603 patients recruited to the study, 1,798
received bicalutamide 150 mg and 1,805 received stan-
dard care alone. Objective disease progression was deter-
mined by a positive bone scan, or other bio-imaging tech-
niques e.g. computed tomography, magnetic resonance
imaging or ultrasound scan. Changes in PSA or clinical
examination findings alone were not considered to be evi-
dence of objective progression.
After a median follow-up of 2.6 years, the risk of objec-
tive progression of disease was significantly reduced (by
43%) in patients receiving bicalutamide 150 mg com-
pared with those receiving standard care alone (HR 0.57;
95% CI 0.48, 0.69; p !! 0.0001; fig. 3) [22].
The incidence of bone scan-confirmed progression or
death indicates development of metastatic disease. Devel-
opment of metastatic disease is an important prognostic
factor for patients with prostate cancer, as survival is
decreased in patients with metastatic disease [23]. The
incidence of positive bone scans was reduced in the bica-
lutamide 150 mg group (9.1%) compared with the stan-
dard care alone group (12.4%; fig. 4).
The benefits of bicalutamide 150 mg were seen across
the patient population studied, regardless of standard
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Fig. 5. Incidence of objective progression after treatment with bicalutamide 150 mg in addition to standard care or
standard care alone classified by (a) prior therapy and (b) stage of disease [22] (reproduced with kind permission from
Elsevier Science).
Table 2. Adverse events in Trial 24 in the EPC programme [22]
(adapted with kind permission from Elsevier Science)
Bicalutamide
150 mg, %
(n = 1,798)
Standard care
alone, %
(n = 1,805)
Gynaecomastia alone 17.4 5.3
Breast pain alone 17.6 3.1
Gynaecomastia plus breast pain 47.5 2.1
Hot flushes 9.3 4.6
Impotence 8.0 5.3
Asthenia 7.2 6.1
Weight gain 5.6 2.6
Diarrhoea 5.1 6.3
Loss of libido 2.6 0.6
Elevated liver enzymes 2.7 0.6
therapy or disease stage. In patients who had previously
undergone therapy of curative intent, a lower incidence of
objective progression was observed in patients receiving
bicalutamide 150 mg than in those receiving standard
care alone (7.4 vs. 13.9%, respectively). In patients who
were candidates for watchful waiting, the incidence of
objective progression was also lower in patients who
received bicalutamide 150 mg compared with those who
received standard care alone (15.0 vs. 20.3%, respective-
ly). In patients with localized disease, fewer of those
receiving bicalutamide 150 mg progressed than those
receiving standard care alone (8.6 vs. 12.0%, respective-
ly). In patients with locally advanced disease a larger dif-
ference was apparent (12.7 vs. 24.4%, respectively; fig. 5)
[22].
These results were supported by data on PSA progres-
sion. PSA progression was defined as at least a doubling in
PSA from baseline (91% of patients receiving radical
prostatectomy had a PSA concentration of !1 ng/ml), or
any objective clinical progression or death (i.e. biochemi-
cal and clinical progression-free survival). Risk of PSA
progression was significantly reduced (by 63%) in the
bicalutamide 150 mg group, with only 15% of patients
receiving bicalutamide 150 mg experiencing PSA progres-
sion at the time of analysis compared with 33% of
patients receiving standard care alone (HR 0.37; 95% CI
0.32, 0.43; p !! 0.0001). Only 260 (7.2%) of the patients
(123 receiving bicalutamide 150 mg vs. 137 receiving
standard care alone) have died at the time of this first
analysis, thus preventing a formal statistical analysis, and
therefore longer follow-up is needed to provide meaning-
ful data on survival.
The tolerability profile of bicalutamide 150 mg was as
would be expected from its pharmacology. Gynaecomas-
tia and breast pain were the most frequent side effects in
the bicalutamide 150 mg group, but the incidence of hot
flushes, impotence and loss of libido were relatively low
(table 2) [22]. There was a low incidence of abnormal liver
function tests (2.7 vs. 0.6%) and rises were frequently
transient and rarely severe.
Withdrawal rates were similar in the bicalutamide
150 mg and standard care alone groups (40.3 vs. 37.2%,
respectively). Withdrawals due to gynaecomastia and
breast pain were 15.4% in patients receiving bicalutamide
150 mg, compared with 0.5% in patients receiving stan-
dard care alone. More patients in the bicalutamide
150 mg group withdrew due to side effects compared with
the standard care alone group (24.5 vs. 7.7%, respective-
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ly), but fewer patients in the bicalutamide 150 mg group
withdrew due to objectively confirmed disease progres-
sion than in the standard care alone group (2.8 vs. 10.8%,
respectively).
These first results from the EPC programme show that
bicalutamide 150 mg as an immediate therapy, either
alone or as adjuvant to primary therapy, reduces disease
progression for most patients, with acceptable side effects.
Therefore, bicalutamide 150 mg may be a suitable prima-
ry or adjuvant therapy for the long-term treatment of
patients with localized or locally advanced prostate can-
cer who are at risk of tumour progression. As early diagno-
sis of prostate cancer improves, increasing numbers of
patients with localized disease are likely to be identified
and these patients will require an effective and well-toler-
ated treatment regimen.
Conclusion
Adjuvant hormonal therapies offer an extended period
of progression-free survival and may improve overall sur-
vival in some patients.
The first results from a study in the EPC programme,
the largest ever international prostate cancer programme
to date, show a statistically significant benefit for bicalu-
tamide 150 mg in reducing the risk of objective progres-
sion when given as immediate therapy either alone or as
adjuvant to treatment of curative intent in patients with
localized or locally advanced prostate cancer. Survival
data are eagerly awaited.
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